Condition: X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) · Sponsor: EspeRare Foundation
This is an open-label, prospective, genotype-match controlled for primary estimand, non randomized, multicenter, international Phase 2 clinical trial designed to investigate the efficacy and safety of ER004 administered intraamniotically as a treatment for unborn XLHED male subjects.
This description comes directly from the study's public registry record.
Agnes Jaulent · +41 22 794 4004 · Info.er004@esperare.org
Marlène Guiraud · +33 5 34 50 60 00 · contact.edelife@pierre-fabre.com
Always discuss trial participation with your own doctor first.
| Cedars-Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| Washington University | St Louis, Missouri, United States | Recruiting |
| Hôpital Necker - Enfants Malades | Paris, Paris, France | Recruiting |
| Universitaetsklinikum Erlangen | Erlangen, Bavaria, Germany | Recruiting |
| Universitaetsklinikum Leipzig AoeR | Leipzig, Saxony, Germany | Recruiting |
| IRCCS Ca' Granda Ospedale Policlinico | Milan, Italy | Recruiting |
| Hospital Universitario Virgen de la Arrixaca | El Palmar, Murcia, Spain | Recruiting |
| University Hospital of Wales Cardiff and Vale University Local Health | Cardiff, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04980638